Provided by Tiger Trade Technology Pte. Ltd.

BioNTech SE

102.92
+0.80000.78%
Post-market: 103.080.1600+0.16%19:51 EDT
Volume:777.60K
Turnover:80.77M
Market Cap:26.04B
PE:-18.65
High:104.98
Open:103.52
Low:102.78
Close:102.12
52wk High:124.00
52wk Low:79.52
Shares:253.00M
Float Shares:105.00M
Volume Ratio:0.85
T/O Rate:0.74%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.5189
EPS(LYR):-5.5184
ROE:-5.88%
ROA:-3.56%
PB:1.15
PE(LYR):-18.65

Loading ...

Sanofi says COVID-19 vaccine showed better tolerability than Moderna’s

TIPRANKS
·
3 hours ago

BioNTech’s Malaria mRNA Vaccine Trial Reaches Completion: What Investors Should Watch

TIPRANKS
·
Yesterday

BioNTech And Boehringer Trial Adds Dimension To Small Cell Lung Cancer Story

Simply Wall St.
·
Apr 16

Kongsberg Gruppen downgraded to Hold from Buy at Nordea

TIPRANKS
·
Apr 16

Deutsche Boerse (0H3T) was upgraded to a Buy Rating at Warburg Research

TIPRANKS
·
Apr 15

Evotec names Ingrid Müller COO, effective May 1, 2026

Reuters
·
Apr 15

BioNTech (BNTX) Is Up 9.8% After Strong Phase 2 HER2 ADC Data - Has The Bull Case Changed?

Simply Wall St.
·
Apr 15

Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Cigna (CI) and BioNTech SE (BNTX)

TIPRANKS
·
Apr 13

BioNTech Says Endometrial Cancer Drug Met Primary Endpoint in Phase 2 Study

MT Newswires Live
·
Apr 13

Trastuzumab Pamirtecan Meets Primary Efficacy Endpoint In Phase 2 Endometrial Cancer Cohort

Reuters
·
Apr 13

BioNTech announce Phase 2 cohort of BNT323 met primary efficacy endpoint

TIPRANKS
·
Apr 13

BioNTech Phase 2 endometrial cancer trial shows 48% response for trastuzumab pamirtecan

Reuters
·
Apr 11

BioNTech SE ADR Advances 3.8%, Outperforms Market

Dow Jones
·
Apr 11

BioNTech Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Apr 10

BioNTech price target raised to $126 from $125 at Morgan Stanley

TIPRANKS
·
Apr 10

Sanofi becomes market authorization holder for Nuvaxovid in Canada

TIPRANKS
·
Apr 09

Invivyd Stock Surges As FDA Alignment Boosts COVID-19 Program

Benzinga_recent_news
·
Apr 09

Invivyd Says Study of Potential COVID-19 Treatment Shows 'High End' Efficacy; Measles Candidate Introduced

MT Newswires Live
·
Apr 09

BioNTech, Boehringer Ingelheim team up on Phase Ib/II small cell lung cancer trial

Reuters
·
Apr 09

Invivyd Advances COVID-19 Program and Launches Measles Antibody

TIPRANKS
·
Apr 09